EUVIMEDEUVIMED entdecken
Crossref

Peripheral CD8+PD-1+ T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer

Wenwen Guo, Tianyun Qiao, Hui Li, Yong Zhao, Jing Qin, Caiqin Zhang, Changhong Shi

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Wenwen Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China; Clinical Research Center, Xi…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant immunotherapy has shown promising clinical activity in the treatment of early non-small cell lung cancer (NSCLC); however, further clarification of the specific mechanism and identification of biomarkers are imperative prior to implementing it as a daily practice. The study investigated the reprogramming of T cells in both tumor and peripheral blood following neoadjuvant chemoimmunotherapy in a preclinical NSCLC mouse model engrafted with a human immune system. Samples were also collected from 21 NSCLC patients (Stage IA-IIIB) who received neoadjuvant chemoimmunotherapy, and the dynamics of potential biomarkers within these samples were measured and further subjected to correlation analysis with prognosis. Further, we initially investigated the sources of the potential biomarkers. We observed in the humanized mouse model, neoadjuvant chemoimmunotherapy could prevent postoperative recurrence and metastasis by increasing the frequency and cytotoxicity of CD8+ T cells in both peripheral blood (p < 0.001) and tumor immune microenvironment (TIME) (p < 0.001). The kinetics of peripheral CD8+PD-1+ T cells reflected the changes in the TIME and pathological responses, ultimately predicting survival outcome of mice. In the clinical cohort, patients exhibiting an increase in these T cells post-treatment had a higher rate of complete or major pathological response (p < 0.05) and increased immune infiltration (p = 0.0012, r = 0.792). We identified these T cells originating from tumor draining lymph nodes and subsequently entering the TIME. In conclusion, the kinetics of peripheral CD8+PD-1+ T cells can serve as a predictor for changes in TIME and optimal timing for surgery, ultimately reflecting the outcomes of neoadjuvant chemoimmunotherapy in both preclinical and clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesNeoadjuvant TherapyLung NeoplasmsProgrammed Cell Death 1 ReceptorBiomarkers, TumorImmunotherapyTumor MicroenvironmentAnimalsHumansMiceFemaleMaleMiddle AgedAgedPrognosisXenograft Model Antitumor Assays

Stichwörter der Autor:innen

BiomarkerCD8(+) T cellHumanized mouse modelNeoadjuvant chemoimmunotherapyNon-small cell lung cancer

Substanzen

Programmed Cell Death 1 ReceptorBiomarkers, TumorPDCD1 protein, human

Autor:innen und Institutionen

  • Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China; Clinical Research Center, Xianyang Central Hospital, Xianyang, Shaanxi, 712099, China.
  • Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
  • Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
  • Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China. Electronic address: zhangcaiqin@fmmu.edu.cn.
  • Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China. Electronic address: changhong@fmmu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, W., Qiao, T., Li, H., Zhao, Y., Qin, J., Zhang, C., & Shi, C. (2024). Peripheral CD8+PD-1+ T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217073

Vancouver

Guo W, Qiao T, Li H, Zhao Y, Qin J, Zhang C, et al. Peripheral CD8+PD-1+ T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217073

BibTeX
@article{Guo2024,
  author = {Guo, Wenwen and Qiao, Tianyun and Li, Hui and Zhao, Yong and Qin, Jing and Zhang, Caiqin and Shi, Changhong},
  title = {Peripheral CD8+PD-1+ T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217073}
}
Kostenlos starten →